News & Updates

Show Multimedia Only
Serum osteopontin levels predicts response to treatment in unresectable HCC

Serum osteopontin levels predicts response to treatment in unresectable HCC

25 May 2023

Among patients with unresectable hepatocellular carcinoma (HCC) scheduled to receive standard combination therapy with atezolizumab plus bevacizumab, those with high levels of serum osteopontin at baseline are likely to have poor response to treatment, as shown in a study.

25 May 2023
Panitumumab plus trifluridine-tipiracil confers survival advantage in RAS wild-type MCRC

Panitumumab plus trifluridine-tipiracil confers survival advantage in RAS wild-type MCRC

21 May 2023

In the third-line treatment of patients with refractory RAS wild-type metastatic colorectal cancer (MCRC), use of panitumumab plus the standard-of-care trifluridine-tipiracil appears to prolong progression-free survival (PFS) when compared with trifluridine-tipiracil alone, according to data from a phase II study.

21 May 2023